Lidbac 1200mg Tablet SR contains Linezolid, an oxazolidinone-class antibiotic effective against a broad spectrum of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). This sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and optimizing antibacterial efficacy. Lidbac 1200mg is indicated for the treatment of complicated skin and soft tissue infections, community-acquired pneumonia, and nosocomial pneumonia caused by susceptible strains. Linezolid exerts its bacteriostatic action by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of the initiation complex. The sustained-release mechanism allows for twice-daily dosing, reducing peak-related adverse effects while maintaining effective drug levels. Common side effects may include gastrointestinal disturbances, headache, and transient hematological changes; therefore, regular monitoring of blood counts is recommended during prolonged therapy. Caution is advised in patients with a history of myelosuppression or serotonin syndrome, as Linezolid is a weak, reversible monoamine oxidase inhibitor. Lidbac 1200mg Tablet SR should be administered under medical supervision, with dosage adjustments based on clinical response and renal function. It is contraindicated in patients with hypersensitivity to Linezolid or any formulation components.